会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • A METHOD FOR GENERATING REFERENCE CONTROLS FOR PHARMACOGENOMIC TESTING
    • 一种用于产生用于药物生物学测试的参考控制的方法
    • WO2009135180A3
    • 2010-03-18
    • PCT/US2009042608
    • 2009-05-01
    • PARAGONMURPHY MICHAEL PCLARK L SCOTTNAKHLE PAMELA JBUTZ KENNETH G
    • MURPHY MICHAEL PCLARK L SCOTTNAKHLE PAMELA JBUTZ KENNETH G
    • C12N15/02A61K48/00A61P35/00C12N5/10C12N15/52
    • C12Q1/6858C12N9/0071C12Q2545/113
    • Reference controls for use with pharmacogenomic testing, and methods for their identification, preparation, and use, are disclosed. The reference controls can confirm that pharmacogenomic testing correctly identifies individuals that do or do not have the mutation of interest, in both clinical trial and patient treatment settings. The reference controls can be selected to include one or more mutations to be identified, and prescreened to confirm that they bind to one or more of the primers used in the pharmacogenomic testing. The reference controls are human genomic DNA that includes certain identified polymorphisms (mutations) of interest, ideally derived from individuals, pre-selected and optionally properly consented, which have one or more of the polymorphism(s) of interest. The reference controls can be prepared by targeted pre-screening of human patients, by examining the genotype or genetic profile of the patients, isolating cells with the desired mutation, optionally immortalizing the cells, and obtaining DNA from the cells. The prescreening of prospective donors can be targeted based on any of a number of factors, such as genes of interest, mutations within the genes of interest, and membership in a specific ethnic or disease state population. The genomic DNA can be pre-screened for its ability to be detected, using a standard pharmacogenomic test, as including a specific mutation. Examples of mutations of interest include those present in a Phase I or Phase Il metabolic enzyme such as CYP2D6, CYP2C 19, CYP2C9, CYP2C8, and CYP3A5, CYP3A4, CYP2A6, CYP2B6, UGT1A1, DPD, ERCC1, MDR1, ADH2, NAT1 and NAT2 or any other metabolic or disease gene.
    • 公开了用于药物基因组测试的参考对照及其鉴定,制备和使用的方法。 在临床试验和患者治疗环境中,参照对照可以证实药物基因组检测正确地识别出有或没有感兴趣突变的个体。 可以选择参考对照以包括待鉴定的一个或多个突变,并进行预筛选以确认它们与药物基因组测试中使用的一种或多种引物结合。 参考对照是人基因组DNA,其包括某些鉴定的目的多态性(突变),理想地衍生自预先选择的和任选正确同意的个体,其具有一个或多个感兴趣的多态性。 通过检查患者的基因型或遗传概况,分离具有所需突变的细胞,任选地使细胞永生化,以及从细胞中获得DNA,可以通过靶向预筛选人类患者来制备参照对照。 可以基于许多因素,如感兴趣的基因,感兴趣的基因内的突变以及特定种族或疾病状态群体的成员中的任何一个因素来预先预先筛选前瞻性供体。 可以使用标准药物基因组测试将基因组DNA的筛选能力进行预筛选,作为包括特异性突变。 感兴趣的突变的实例包括存在于I期或II期代谢酶如CYP2D6,CYP2C19,CYP2C9,CYP2C8和CYP3A5,CYP3A4,CYP2A6,CYP2B6,UGT1A1,DPD,ERCC1,MDR1,ADH2,NAT1和NAT2中的那些 或任何其他代谢或疾病基因。